ID   MCF-7-TaxR
AC   CVCL_4V97
DR   cancercelllines; CVCL_4V97
DR   Wikidata; Q54904336
RX   PubMed=23514751;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 13
//
RX   PubMed=23514751; DOI=10.1093/carcin/bgt098;
RA   Khongkow M., Olmos Y., Gong C., Gomes A.R., Monteiro L.J., Yague E.,
RA   Cavaco T.B., Khongkow P., Man E.P.S., Laohasinnarong S., Koo C.-Y.,
RA   Harada-Shoji N., Tsang J.W.-H., Coombes R.C., Schwer B., Khoo U.-S.,
RA   Lam E.W.-F.;
RT   "SIRT6 modulates paclitaxel and epirubicin resistance and survival in
RT   breast cancer.";
RL   Carcinogenesis 34:1476-1486(2013).
//